N-ASTHEAL ®, A HERBAL FORMULA FOR THE TREATMENT OF MILD ASTHMA: AN OPEN, SINGLE CENTRIC, NON- COMPARATIVE PILOT STUDY FOR 3 WEEKS

  • Yogendra Kumar Choudhary
  • Shambhu Agarwal
  • Anshul Jain
  • Ashish Jain
  • Mugil Mourya
  • Vandana Kc
  • Jackson P

Abstract

Objective: The aim was to evaluate efficacy and safety of N-Astheal® in a pilot study on 12 patients with mild to moderate bronchial asthma.
Materials and Methods: The study was an open-label, single centric clinical trial conducted by Ethix Pharma at Clinical Research Center, CMC & H,
Bhaisa Khedi, Bhopal, India from 12 March to 30 May 2013. The study was conducted on 12 patients comprised of 8 male and 4 female with an
age range of 18-70 years, all the subjects were with mild to moderate bronchial asthma. Patients with another chronic lung disease (other than
asthma) and those who are suffering from breathlessness due to cardiovascular disorders were excluded. Pregnant or lactating females were also
excluded in the study. The potential subjects were screened and consented. The consented subjects were enrolled in the study and baseline history
was obtained in order to determine the patient’s eligibility for enrollment in the trail. Thereafter all patients underwent a clinical examination,
including hematology, biochemistry, urinalysis and spirometry test. All patients were advised to take N-Astheal twice in a day for a period of 3 weeks.
All patients were followed-up twice after giving N-Astheal and during each follow-up visit, physical examination, vitals examination, spirometry,
acoustic emission monitoring was done. The final assessment was carried out for decrease in the severity and symptoms of asthma, improvement of
forced expiratory volume in one second (FEV1), improvement in forced vital capacity (FVC) and percentage improvement in peak expiratory flow rate
(PEFR). Statistical analysis was performed according to intention-to-treat principles.
Results: The overall response to the treatment by N-Astheal® observed a significant reduction in the severity and symptoms of asthma along with
significant improvement in FEV1 from 65.2% to 74.9% (*p<0.05), FVC from 96.2% to 105.1% (*p<0.05), PEFR from 44.4% to 64.2% (**p<0.01) was
observed from 1st week to 4th week, respectively. This pilot study revealed the beneficial effect of N-Astheal® in acute asthma and similar respiratory
condition.
Conclusion: The present pilot study 3 weeks treatment of N-Astheal® had been promising in treating asthma and similar respiratory conditions and
at the same time the treatment was proved safe as well with a very good patient compliance.

Keywords: Asthma, N-Astheal®, inflammation, Anti-asthmatic agent, Clinical

References

1. Nadia AK, Donald AE, Chiang CY, Marks G, Bissell K. Management of
Asthma: A Guide to Essentials of Good Clinical Practice. 3rd ed. Paris,
France: International Union against Tuberculosis and Lung Diseases
(Union); 2008. p. 6-7.
2. Kim H, Mazza J. Asthma. Allergy Asthma Clin Immunol
2011;7 Suppl 1:S2.
3. Li XM, Brown L. Efficacy and mechanisms of action of traditional
Chinese medicines for treating asthma and allergy. J Allergy Clin
Immunol 2009;123(2):297-306.
4. Huntley A, Ernst E. Herbal medicines for asthma: A systematic review.
Thorax 2000;55(11):925-9.
5. Danish M, Pradeep S, Mishra G, Srivastava S, Jha KK, Khosa RL.
Cassia fistula Linn. (Amulthus) - An important medicinal plant:
A review of its traditional uses, phytochemistry and pharmacological
properties. J Nat Prod Plant Resour 2011;1(1):101-18.
6. Kumar S, Agnihotri VK, Thakur S, Verma A, Saxena RC, Soni KK.
Some important medicinal plants used in the treatment of Asthma - A
review. Int J Pharm Sci Res 2012;3(10):500-2.
7. Fatima S, Khalid HJ, Muhammad FL. Ethnopharmacological studies on
antispasmodic, bronchodilator and antiplatelet aggregation activities of
Blepharis edulis, Pers. Asian Nat Appl Sci 2012;1(1):33-45.
8. Aggarwal BB, Prasad S, Reuter S, Kannappan R, Yadev VR, Park B, et al.
Identification of novel anti-inflammatory agents from Ayurvedic medicine
for prevention of chronic diseases: “Reverse pharmacology” and “bedside
to bench” approach. Curr Drug Targets 2011;12(11):1595-653.
9. Sharma V, Agrawal RC. Glycyrrhiza glabra - A plant for the future.
Mintage J Pharm Med Sci 2013;2(3):15-20.
10. Jatav VS, Singh SK, Khatri P, Sharma AK. Recent pharmacological
trends of Glycyrrhiza glabra Linn. Int J Pharm Front Res
2011;1(1):170-85.
11. Li XM. Traditional Chinese herbal remedies for asthma and food
allergy. J Allergy Clin Immunol 2007;120(1):25-31.
12. Ernst E. Use of unconventional therapies in child-hood asthma. Pediatr
Allergy Immunol 1998;12:29-32.
Statistics
342 Views | 351 Downloads
How to Cite
Choudhary, Y. K., S. Agarwal, A. Jain, A. Jain, M. Mourya, V. Kc, and J. P. “N-ASTHEAL ®, A HERBAL FORMULA FOR THE TREATMENT OF MILD ASTHMA: AN OPEN, SINGLE CENTRIC, NON- COMPARATIVE PILOT STUDY FOR 3 WEEKS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 7, no. 4, Sept. 2014, pp. 3-6, https://innovareacademics.in/journals/index.php/ajpcr/article/view/1507.
Section
Original Article(s)